CN Patent

CN115666531A — 促性腺激素释放激素拮抗剂的组合固体口服剂型

Assigned to Sumitomo Pharma Co Ltd · Expires 2023-01-31 · 3y expired

What this patent protects

本公开包含组合固体口服剂型，其具有40mg N‑(4‑(1‑(2,6‑二氟苄基)‑5‑((二甲基氨基)甲基)‑3‑(6‑甲氧基‑3‑哒嗪基)‑2,4‑二氧代‑1,2,3,4‑四氢噻吩并[2,3‑d]嘧啶‑6‑基)苯基)‑N'‑甲氧基脲或其对应量的药学上可接受的盐，以及激素替代药物。还提供了用于制备和使用所述固体口服剂型的方法。

USPTO Abstract

本公开包含组合固体口服剂型，其具有40mg N‑(4‑(1‑(2,6‑二氟苄基)‑5‑((二甲基氨基)甲基)‑3‑(6‑甲氧基‑3‑哒嗪基)‑2,4‑二氧代‑1,2,3,4‑四氢噻吩并[2,3‑d]嘧啶‑6‑基)苯基)‑N'‑甲氧基脲或其对应量的药学上可接受的盐，以及激素替代药物。还提供了用于制备和使用所述固体口服剂型的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115666531A
Jurisdiction
CN
Classification
—
Expires
2023-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.